Table 1.
New agents in HL
| Study | Phase | Drug | Mechanism of action | Route | N | ORR, N (%) | CR | PR | SD | Median PFS |
|---|---|---|---|---|---|---|---|---|---|---|
| Younes et al, 20121 | II | Panobinsotat | Pan HDAC | PO | 129 | 35 (27%) | 5 (4%) | 30 (23%) | 71 (55%) | 6.1 mo |
| Batlevi et al, 2015 (in process) | II | Entinostat | iso-spec HDAC | PO | 49 | 6 (12%) | 0 (0%) | 6 (12%) | 6 (12%) | 5.5 mo |
| Ansell et al, 20152 | I | Nivolumab | immune checkpoint | IV | 23 | 20 (87%) | 4 (17%) | 16 (70%) | 3 (13%) | 86% at 24 wk |
| Younes et al, 20123 | II | Brentuximab vedotin | ADC | IV | 102 | 76 (75%) | 35 (34%) | 41 (40%) | 22 (22%) | 5.6 mo |
| Armand et al, 2015 Abstract4 | I | Pembrolizumab | Immune checkpoint | IV | 31 | 20 (66%) | 5 (16%) | 15 (48%) | 7 (23%) | Not reported |
| Johnston et al, 2010, Abstract 20125,6 | II | Everolimus | MTOR inhibitor | PO | 57 | 24 (42%) | 5 (9%) | 19 (33%) | 20 (35%) | 6 mo |
| Fehniger et al, 2011 Abstract7 | II | Lenalidomide | Immune modulator | PO | 38 | 7 (18%) | 1 (3%) | 6 (16%) | 5 (13%) | Not reported |